文献速递血栓与止血

通用型罗米司亭治疗北印度三甲中心儿童持续性或慢性免疫性血小板减少症的经验

Generic romiplostim for children with persistent or chronic immune thrombocytopenia: Experience from a tertiary care centre in North India.
PubMed 文献 · Br J Haematol · 2022-04-25

该研究纳入45例持续性或慢性免疫性血小板减少症(ITP)患儿,40例接受通用型罗米司亭5 mcg/kg/周治疗20周,第20周65%(26/40)患儿血小板反应(血小板计数升至50×10^9/L以上且未用救援药物),减停后22/40患儿维持持续血小板反应,无严重不良事件。

要点

  • 通用型罗米司亭5 mcg/kg/周治疗20周,65%(26/40)患儿出现血小板反应。
  • 减停罗米司亭后,22/40患儿维持持续血小板反应。
  • 无不良事件被认为严重或导致停药。

核心结论

  • 通用型罗米司亭在持续性或慢性ITP患儿中耐受良好且有效。

研究设计与样本

  • 研究纳入45例持续性或慢性ITP患儿,其中5例停药,40例纳入分析,时间为2019至2020年。
  • 患儿接受罗米司亭5 mcg/kg/周治疗20周,第1、3、20、26周评估血小板计数。
  • 第20周后血小板计数≥50×10^9/L者逐渐减停药物并监测至第26周。

主要发现

  • 入组时中位血小板计数为11×10^9/L(IQR 23×10^9/L)。
  • 13/40例患儿既往接受过≥3线ITP治疗。
  • 第20周时26/40(65%)患儿出现血小板反应(血小板计数升至50×10^9/L以上且未用救援药物)。
  • 12/40例患儿使用了救援药物。
  • 减停罗米司亭后22/40例患儿维持持续血小板反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombopoietin receptor agonists are important therapeutic option in children with immune thrombocytopenia (ITP). We evaluated the response, efficacy, safety of a generic form of romiplostim manufactured in India for treating children with persistent/chronic ITP at our centre. Study of 45 children with persistent/chronic ITP was conducted of which 5 discontinued and 40 were included between 2019-2020. Patients received romiplostim for 20 weeks, at a dose of 5 mcg/kg/week. Platelet count at week 1, 3, 20 and 26 was assessed. Predesigned algorithm was used for dose adjustment. After 20 weeks, patients who had platelet count of 50 × 109/L or above were tapered off medication and monitored till 26 weeks. Median platelet count at enrolment was 11 x 109/L (IQR 23 X 109/L). 13/40 children had received >/= three lines of prior ITP therapy. Platelet response (platelet count rise to more than 50×109/L without rescue medications) observed in 26 (65%) patients at week 20. Rescue medication was used in 12/40 children. Sustained platelet response after tapering and stopping romiplostim observed in 22/40 children. No adverse events were considered serious or led to discontinuation of treatment. Our data demonstrated generic romiplostim is well tolerated and efficacious in children with persistent/chronic ITP.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mareddy C, Kalra M, Sachdeva A, et al. Generic romiplostim for children with persistent or chronic immune thrombocytopenia: Experience from a tertiary care centre in North India. Br J Haematol. 2022. PMID: 35467751. doi:10.1111/bjh.18126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。